FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction

Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical investigation 2018-01, Vol.128 (1), p.267-280
Hauptverfasser: Zhou, Shi-Yi, Gillilland, 3rd, Merritt, Wu, Xiaoyin, Leelasinjaroen, Pornchai, Zhang, Guanpo, Zhou, Hui, Ye, Bo, Lu, Yuanxu, Owyang, Chung
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 280
container_issue 1
container_start_page 267
container_title The Journal of clinical investigation
container_volume 128
creator Zhou, Shi-Yi
Gillilland, 3rd, Merritt
Wu, Xiaoyin
Leelasinjaroen, Pornchai
Zhang, Guanpo
Zhou, Hui
Ye, Bo
Lu, Yuanxu
Owyang, Chung
description Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.
doi_str_mv 10.1172/JCI92390
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5749529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A523063026</galeid><sourcerecordid>A523063026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-60924db360e5094c51d534ac41a9aa72ee8171c42e9ea112017ea29a128a52623</originalsourceid><addsrcrecordid>eNpdUdtu1DAUtBCILgWJL0CRkCpeAr4m8QvSaqGlqKg8wLN11jnbdeXYi51Uyt_j9MblydLxzJwzM4S8ZvQ9Yy3_8HVzrrnQ9AlZMaW6uuOie0pWlHJW61Z0R-RFzteUMimVfE6OuOaUy1asyHx6-enb-nvVOxyrIfaThxFzdeOyxQS-CtE6i4fRxVBt58q7QzxEP2ewdg_J9VgP2LvC6SsXCnN0obBc2HkYBrilQeirLaTkMFX9nHdTsMv8JXm2A5_x1f17TH6efv6x-VJfXJ6db9YXtZW6HeuGai77rWgoKqqlVaxXQoKVDDRAyxE71jIrOWoExjhlLQLXwHgHijdcHJOPd7qHaVtutRjGYswckhsgzSaCM__-BLc3V_HGqFZqxXUReHcvkOKvqVg0w5KO9xAwTtmwknAJWne0QN_-B72OUyqJZCNo21DVML0IntyhrsCj2SP4cZ-jn5ZUslkrLmhTFJs_m22KOSfcPV7NqFmKNw_FF-ibv10-Ah-aFr8BHT6pjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3076056199</pqid></control><display><type>article</type><title>FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhou, Shi-Yi ; Gillilland, 3rd, Merritt ; Wu, Xiaoyin ; Leelasinjaroen, Pornchai ; Zhang, Guanpo ; Zhou, Hui ; Ye, Bo ; Lu, Yuanxu ; Owyang, Chung</creator><creatorcontrib>Zhou, Shi-Yi ; Gillilland, 3rd, Merritt ; Wu, Xiaoyin ; Leelasinjaroen, Pornchai ; Zhang, Guanpo ; Zhou, Hui ; Ye, Bo ; Lu, Yuanxu ; Owyang, Chung</creatorcontrib><description>Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI92390</identifier><identifier>PMID: 29202473</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Animals ; Antibiotics ; Bacteria ; Breath tests ; Colon ; Cytokines ; Diet ; Dietary Carbohydrates - adverse effects ; Dietary Carbohydrates - pharmacology ; Digestive system ; Disaccharides ; Dysbacteriosis ; Dysbiosis - chemically induced ; Dysbiosis - genetics ; Dysbiosis - metabolism ; Dysbiosis - microbiology ; Feces ; Fermented food ; Gastrointestinal Microbiome ; Gastrointestinal tract ; Gene Knockdown Techniques ; Health aspects ; Hyperalgesia ; Hypotheses ; Inflammation ; Intestine ; Intestines - microbiology ; Irritable bowel syndrome ; Irritable Bowel Syndrome - chemically induced ; Irritable Bowel Syndrome - genetics ; Irritable Bowel Syndrome - metabolism ; Irritable Bowel Syndrome - microbiology ; Lipopolysaccharides ; Lipopolysaccharides - toxicity ; Male ; Microbiota ; Monosaccharides ; Nociception ; Nutrient deficiency ; Oligosaccharides ; Pain perception ; Pathology ; Permeability ; Polyols ; Rats ; Rats, Wistar ; TLR4 protein ; Toll-Like Receptor 4 - genetics ; Toll-Like Receptor 4 - metabolism ; Toll-like receptors</subject><ispartof>The Journal of clinical investigation, 2018-01, Vol.128 (1), p.267-280</ispartof><rights>COPYRIGHT 2018 American Society for Clinical Investigation</rights><rights>Copyright American Society for Clinical Investigation Jan 2018</rights><rights>Copyright © 2018, American Society for Clinical Investigation 2018 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-60924db360e5094c51d534ac41a9aa72ee8171c42e9ea112017ea29a128a52623</citedby><cites>FETCH-LOGICAL-c497t-60924db360e5094c51d534ac41a9aa72ee8171c42e9ea112017ea29a128a52623</cites><orcidid>0000-0003-4109-9898 ; 0000-0002-6750-8541</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749529/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749529/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29202473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Shi-Yi</creatorcontrib><creatorcontrib>Gillilland, 3rd, Merritt</creatorcontrib><creatorcontrib>Wu, Xiaoyin</creatorcontrib><creatorcontrib>Leelasinjaroen, Pornchai</creatorcontrib><creatorcontrib>Zhang, Guanpo</creatorcontrib><creatorcontrib>Zhou, Hui</creatorcontrib><creatorcontrib>Ye, Bo</creatorcontrib><creatorcontrib>Lu, Yuanxu</creatorcontrib><creatorcontrib>Owyang, Chung</creatorcontrib><title>FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.</description><subject>Animals</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Breath tests</subject><subject>Colon</subject><subject>Cytokines</subject><subject>Diet</subject><subject>Dietary Carbohydrates - adverse effects</subject><subject>Dietary Carbohydrates - pharmacology</subject><subject>Digestive system</subject><subject>Disaccharides</subject><subject>Dysbacteriosis</subject><subject>Dysbiosis - chemically induced</subject><subject>Dysbiosis - genetics</subject><subject>Dysbiosis - metabolism</subject><subject>Dysbiosis - microbiology</subject><subject>Feces</subject><subject>Fermented food</subject><subject>Gastrointestinal Microbiome</subject><subject>Gastrointestinal tract</subject><subject>Gene Knockdown Techniques</subject><subject>Health aspects</subject><subject>Hyperalgesia</subject><subject>Hypotheses</subject><subject>Inflammation</subject><subject>Intestine</subject><subject>Intestines - microbiology</subject><subject>Irritable bowel syndrome</subject><subject>Irritable Bowel Syndrome - chemically induced</subject><subject>Irritable Bowel Syndrome - genetics</subject><subject>Irritable Bowel Syndrome - metabolism</subject><subject>Irritable Bowel Syndrome - microbiology</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - toxicity</subject><subject>Male</subject><subject>Microbiota</subject><subject>Monosaccharides</subject><subject>Nociception</subject><subject>Nutrient deficiency</subject><subject>Oligosaccharides</subject><subject>Pain perception</subject><subject>Pathology</subject><subject>Permeability</subject><subject>Polyols</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>TLR4 protein</subject><subject>Toll-Like Receptor 4 - genetics</subject><subject>Toll-Like Receptor 4 - metabolism</subject><subject>Toll-like receptors</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdUdtu1DAUtBCILgWJL0CRkCpeAr4m8QvSaqGlqKg8wLN11jnbdeXYi51Uyt_j9MblydLxzJwzM4S8ZvQ9Yy3_8HVzrrnQ9AlZMaW6uuOie0pWlHJW61Z0R-RFzteUMimVfE6OuOaUy1asyHx6-enb-nvVOxyrIfaThxFzdeOyxQS-CtE6i4fRxVBt58q7QzxEP2ewdg_J9VgP2LvC6SsXCnN0obBc2HkYBrilQeirLaTkMFX9nHdTsMv8JXm2A5_x1f17TH6efv6x-VJfXJ6db9YXtZW6HeuGai77rWgoKqqlVaxXQoKVDDRAyxE71jIrOWoExjhlLQLXwHgHijdcHJOPd7qHaVtutRjGYswckhsgzSaCM__-BLc3V_HGqFZqxXUReHcvkOKvqVg0w5KO9xAwTtmwknAJWne0QN_-B72OUyqJZCNo21DVML0IntyhrsCj2SP4cZ-jn5ZUslkrLmhTFJs_m22KOSfcPV7NqFmKNw_FF-ibv10-Ah-aFr8BHT6pjQ</recordid><startdate>20180102</startdate><enddate>20180102</enddate><creator>Zhou, Shi-Yi</creator><creator>Gillilland, 3rd, Merritt</creator><creator>Wu, Xiaoyin</creator><creator>Leelasinjaroen, Pornchai</creator><creator>Zhang, Guanpo</creator><creator>Zhou, Hui</creator><creator>Ye, Bo</creator><creator>Lu, Yuanxu</creator><creator>Owyang, Chung</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4109-9898</orcidid><orcidid>https://orcid.org/0000-0002-6750-8541</orcidid></search><sort><creationdate>20180102</creationdate><title>FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction</title><author>Zhou, Shi-Yi ; Gillilland, 3rd, Merritt ; Wu, Xiaoyin ; Leelasinjaroen, Pornchai ; Zhang, Guanpo ; Zhou, Hui ; Ye, Bo ; Lu, Yuanxu ; Owyang, Chung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-60924db360e5094c51d534ac41a9aa72ee8171c42e9ea112017ea29a128a52623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Breath tests</topic><topic>Colon</topic><topic>Cytokines</topic><topic>Diet</topic><topic>Dietary Carbohydrates - adverse effects</topic><topic>Dietary Carbohydrates - pharmacology</topic><topic>Digestive system</topic><topic>Disaccharides</topic><topic>Dysbacteriosis</topic><topic>Dysbiosis - chemically induced</topic><topic>Dysbiosis - genetics</topic><topic>Dysbiosis - metabolism</topic><topic>Dysbiosis - microbiology</topic><topic>Feces</topic><topic>Fermented food</topic><topic>Gastrointestinal Microbiome</topic><topic>Gastrointestinal tract</topic><topic>Gene Knockdown Techniques</topic><topic>Health aspects</topic><topic>Hyperalgesia</topic><topic>Hypotheses</topic><topic>Inflammation</topic><topic>Intestine</topic><topic>Intestines - microbiology</topic><topic>Irritable bowel syndrome</topic><topic>Irritable Bowel Syndrome - chemically induced</topic><topic>Irritable Bowel Syndrome - genetics</topic><topic>Irritable Bowel Syndrome - metabolism</topic><topic>Irritable Bowel Syndrome - microbiology</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - toxicity</topic><topic>Male</topic><topic>Microbiota</topic><topic>Monosaccharides</topic><topic>Nociception</topic><topic>Nutrient deficiency</topic><topic>Oligosaccharides</topic><topic>Pain perception</topic><topic>Pathology</topic><topic>Permeability</topic><topic>Polyols</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>TLR4 protein</topic><topic>Toll-Like Receptor 4 - genetics</topic><topic>Toll-Like Receptor 4 - metabolism</topic><topic>Toll-like receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Shi-Yi</creatorcontrib><creatorcontrib>Gillilland, 3rd, Merritt</creatorcontrib><creatorcontrib>Wu, Xiaoyin</creatorcontrib><creatorcontrib>Leelasinjaroen, Pornchai</creatorcontrib><creatorcontrib>Zhang, Guanpo</creatorcontrib><creatorcontrib>Zhou, Hui</creatorcontrib><creatorcontrib>Ye, Bo</creatorcontrib><creatorcontrib>Lu, Yuanxu</creatorcontrib><creatorcontrib>Owyang, Chung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Shi-Yi</au><au>Gillilland, 3rd, Merritt</au><au>Wu, Xiaoyin</au><au>Leelasinjaroen, Pornchai</au><au>Zhang, Guanpo</au><au>Zhou, Hui</au><au>Ye, Bo</au><au>Lu, Yuanxu</au><au>Owyang, Chung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2018-01-02</date><risdate>2018</risdate><volume>128</volume><issue>1</issue><spage>267</spage><epage>280</epage><pages>267-280</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>29202473</pmid><doi>10.1172/JCI92390</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-4109-9898</orcidid><orcidid>https://orcid.org/0000-0002-6750-8541</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 2018-01, Vol.128 (1), p.267-280
issn 0021-9738
1558-8238
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5749529
source MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Animals
Antibiotics
Bacteria
Breath tests
Colon
Cytokines
Diet
Dietary Carbohydrates - adverse effects
Dietary Carbohydrates - pharmacology
Digestive system
Disaccharides
Dysbacteriosis
Dysbiosis - chemically induced
Dysbiosis - genetics
Dysbiosis - metabolism
Dysbiosis - microbiology
Feces
Fermented food
Gastrointestinal Microbiome
Gastrointestinal tract
Gene Knockdown Techniques
Health aspects
Hyperalgesia
Hypotheses
Inflammation
Intestine
Intestines - microbiology
Irritable bowel syndrome
Irritable Bowel Syndrome - chemically induced
Irritable Bowel Syndrome - genetics
Irritable Bowel Syndrome - metabolism
Irritable Bowel Syndrome - microbiology
Lipopolysaccharides
Lipopolysaccharides - toxicity
Male
Microbiota
Monosaccharides
Nociception
Nutrient deficiency
Oligosaccharides
Pain perception
Pathology
Permeability
Polyols
Rats
Rats, Wistar
TLR4 protein
Toll-Like Receptor 4 - genetics
Toll-Like Receptor 4 - metabolism
Toll-like receptors
title FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T01%3A41%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FODMAP%20diet%20modulates%20visceral%20nociception%20by%20lipopolysaccharide-mediated%20intestinal%20inflammation%20and%20barrier%20dysfunction&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Zhou,%20Shi-Yi&rft.date=2018-01-02&rft.volume=128&rft.issue=1&rft.spage=267&rft.epage=280&rft.pages=267-280&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI92390&rft_dat=%3Cgale_pubme%3EA523063026%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3076056199&rft_id=info:pmid/29202473&rft_galeid=A523063026&rfr_iscdi=true